We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ADAP

Price
0.25
Stock movement down
-0.00 (-1.17%)
Company name
Adaptimmune Therapeutics Plc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
67.06M
Ent value
187.76M
Price/Sales
0.38
Price/Book
0.84
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-10.33%
1 year return
-73.00%
3 year return
-44.50%
5 year return
-52.47%
10 year return
-35.17%
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

DIVIDENDS

ADAP does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales0.38
Price to Book0.84
EV to Sales1.07

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count265.05M
EPS (TTM)-0.18
FCF per share (TTM)-0.22

Income statement

Loading...
Income statement data
Revenue (TTM)175.04M
Gross profit (TTM)166.74M
Operating income (TTM)-49.26M
Net income (TTM)-44.93M
EPS (TTM)-0.18
EPS (1y forward)-0.50

Margins

Loading...
Margins data
Gross margin (TTM)95.26%
Operating margin (TTM)-28.14%
Profit margin (TTM)-25.67%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash116.74M
Net receivables38.61M
Total current assets244.21M
Goodwill0.00
Intangible assets4.28M
Property, plant and equipment138.23M
Total assets317.44M
Accounts payable9.07M
Short/Current long term debt24.63M
Total current liabilities63.46M
Total liabilities237.45M
Shareholder's equity79.99M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-53.66M
Capital expenditures (TTM)2.38M
Free cash flow (TTM)-56.04M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-56.17%
Return on Assets-14.15%
Return on Invested Capital-33.52%
Cash Return on Invested Capital-41.81%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.26
Daily high0.27
Daily low0.25
Daily Volume649K
All-time high21.12
1y analyst estimate0.68
Beta2.18
EPS (TTM)-0.18
Dividend per share-
Ex-div date-
Next earnings date5 Nov 2025

Downside potential

Loading...
Downside potential data
ADAPS&P500
Current price drop from All-time high-98.80%-3.04%
Highest price drop-99.07%-56.47%
Date of highest drop31 Mar 20259 Mar 2009
Avg drop from high-76.41%-11.04%
Avg time to new high424 days12 days
Max time to new high2519 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ADAP (Adaptimmune Therapeutics Plc) company logo
Marketcap
67.06M
Marketcap category
Small-cap
Description
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Employees
506
Investor relations
-
SEC filings
CEO
Adrian Rawcliffe
Country
USA
City
Abingdon
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...